Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate

References

• SilverJKilavRNaveh-ManyTMechanisms of secondary hyperparathyroidismAm J Physiol Renal Physiol20022833F367F37612167586
   PubMed Web of Science ®Google Scholar
• CraverLMarcoMPMartinezIMineral metabolism parameters throughout chronic kidney disease stages 1–5 – achievement of K/DOQI target rangesNephrol Dial Transplant20072241171117617205962
   PubMed Web of Science ®Google Scholar
• BlockGAHulbert-ShearonTELevinNWPortFKAssociation of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national studyAm J Kidney Dis19983146076179531176
   PubMed Web of Science ®Google Scholar
• KestenbaumBSampsonJNRudserKDSerum Phosphate Levels and Mortality Risk among People with Chronic Kidney DiseaseJ Am Soc Nephrol200516252052815615819
   PubMed Web of Science ®Google Scholar
• GaneshSKStackAGLevinNWHulbert-ShearonTPortFKAssociation of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patientsJ Am Soc Nephrol200112102131213811562412
   PubMed Web of Science ®Google Scholar
• JonoSMcKeeMDMurryCEPhosphate regulation of vascular smooth muscle cell calcificationCirc Res2000877E10E1711009570
   PubMed Web of Science ®Google Scholar
• LiXYangHYGiachelliCMRole of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcificationCirc Res200698790591216527991
   PubMed Web of Science ®Google Scholar
• OkunoSIshimuraEKitataniKPresence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patientsAm J Kidney Dis200749341742517336703
   PubMed Web of Science ®Google Scholar
• WilsonPWKauppilaLIO’DonnellCJAbdominal aortic calcific deposits are an important predictor of vascular morbidity and mortalityCirculation2001 20;103111529153411257080
   PubMed Web of Science ®Google Scholar
• KoppleJDEffect of nutrition on morbidity and mortality in maintenance dialysis patientsAm J Kidney Dis1994246100210097985661
   PubMed Web of Science ®Google Scholar
• GoldwasserPMittmanNAntignaniAPredictors of mortality in hemodialysis patientsJ Am Soc Nephrol199339161316228507818
   PubMed Web of Science ®Google Scholar
• CianciarusoBPotaAPisaniAMetabolic effects of two low protein diets in chronic kidney disease stage 4–5 – a randomized controlled trialNephrol Dial Transplant200823263664417981885
   PubMed Web of Science ®Google Scholar
• PohlmeierRVienkenJPhosphate removal and hemodialysis conditionsKidney Int Suppl200178S190S19411169009
   PubMed Web of Science ®Google Scholar
• LeypoldtJKKinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and durationSemin Dial200518540140816191181
   PubMed Web of Science ®Google Scholar
• SheikhMSMaguireJAEmmettMReduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo studyJ Clin Invest198983166732910921
   PubMed Web of Science ®Google Scholar
• MaiMLEmmettMSheikhMSSanta AnaCASchillerLFordtranJSCalcium acetate, an effective phosphorus binder in patients with renal failureKidney Int19893646906952811066
   PubMed Web of Science ®Google Scholar
• ChertowGMRaggiPChasan-TaberSBommerJHolzerHBurkeSKDeterminants of progressive vascular calcification in haemodialysis patientsNephrol Dial Transplant20041961489149615102961
   PubMed Web of Science ®Google Scholar
• GoldsmithDJCovicASambrookPAAckrillPVascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysisNephron199777137439380236
   PubMed Web of Science ®Google Scholar
• GoodmanWGGoldinJKuizonBDCoronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysisN Engl J Med2000342201478148310816185
   PubMed Web of Science ®Google Scholar
• LondonGMGuerinAPMarchaisSJMetivierFPannierBAddaHArterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortalityNephrol Dial Transplant20031891731174012937218
   PubMed Web of Science ®Google Scholar
• RaggiPBoulayAChasan-TaberSCardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?J Am Coll Cardiol2002 20;39469570111849871
   PubMed Web of Science ®Google Scholar
• ChertowGMBurkeSKRaggiPSevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patientsKidney Int200262124525212081584
   PubMed Web of Science ®Google Scholar
• BlockGASpiegelDMEhrlichJEffects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysisKidney Int20056841815182416164659
   PubMed Web of Science ®Google Scholar
• IzumiMMoritaSNishianYSwitching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray filmsRen Fail2008301095295819016145
   PubMed Web of Science ®Google Scholar
• TakeiTOtsuboSUchidaKEffects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysisNephron Clin Pract20081084c278c28318434749
   PubMedGoogle Scholar
• BarretoDVBarretoFDde CarvalhoABPhosphate Binder Impact on Bone Remodeling and Coronary Calcification – Results from the BRiC StudyNephron Clin Pract20081104c273c28319001830
   PubMed Web of Science ®Google Scholar
• BraunlinWZhorovEGuoABile acid binding to sevelamer HClKidney Int200262261161912110025
   PubMed Web of Science ®Google Scholar
• MarcoMPMuraySBetriuACraverLBelartMFernandezETreatment with sevelamer decreases bicarbonate levels in hemodialysis patientsNephron200292249950012218343
   PubMed Web of Science ®Google Scholar
• BrezinaBQunibiWYNolanCRAcid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implicationsKidney Int Suppl200490S39S4515296506
   PubMed Web of Science ®Google Scholar
• SpragueSMA comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonateCurr Med Res Opin200723123167317517991307
   PubMed Web of Science ®Google Scholar
• PennickMDennisKDammentSJAbsolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonateJ Clin Pharmacol200646773874616809799
   PubMed Web of Science ®Google Scholar
• PennickMDennisKDammentSJAbsolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonateJ Clin Pharmacol200646773874616809799
   PubMed Web of Science ®Google Scholar
• DammentSJPennickMClinical pharmacokinetics of the phosphate binder lanthanum carbonateClin Pharmacokinet200847955356318698878
   PubMed Web of Science ®Google Scholar
• JouhanneauPRaisbeckGMYiouFLacourBBanideHDruekeTBGastrointestinal absorption, tissue retention, and urinary excretion of dietary aluminium in rats determined by using 26AlClin Chem1997436 Pt 1102310289191556
   PubMed Web of Science ®Google Scholar
• CoburnJWMischelMGGoodmanWGSaluskyIBCalcium citrate markedly enhances aluminium absorption from aluminium hydroxideAm J Kidney Dis19911767087112042654
   PubMed Web of Science ®Google Scholar
• AutissierVDammentSJHendersonRARelative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride 1J Pharm Sci200796102818282717497733
   PubMed Web of Science ®Google Scholar
• JoyMSFinnWFRandomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemiaAm J Kidney Dis20034219610712830461
   PubMed Web of Science ®Google Scholar
• Al-BaajFSpeakeMHutchisonAJControl of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled studyNephrol Dial Transplant200520477578215703206
   PubMed Web of Science ®Google Scholar
• ChiangSSChenJBYangWCLanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal diseaseClin Nephrol200563646147015960148
   PubMed Web of Science ®Google Scholar
• HutchisonAJMaesBVanwalleghemJEfficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonateNephron Clin Pract20051001c81915809508
   PubMedGoogle Scholar
• HutchisonAJMaesBVanwalleghemJLong-term efficacy and tolerability of lanthanum carbonate: results from a 3-year studyNephron Clin Pract20061022c61c7116224198
   PubMedGoogle Scholar
• HutchisonAJBarnettMEKrauseRKwanJTSiamiGALong-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatmentNephron Clin Pract20081101c15c2318667837
   PubMed Web of Science ®Google Scholar
• FinnWFLanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patientsClin Nephrol200665319120216550750
   PubMed Web of Science ®Google Scholar
• ShigematsuTLanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysisTher Apher Dial2008121556118257813
   PubMed Web of Science ®Google Scholar
• SpragueSMAbboudHQiuPDauphinMZhangPFinnWLanthanum Carbonate Reduces Phosphorus Burden in Patients with CKD Stages 3 and 4: A Randomized TrialClin J Am Soc Nephrol20094117818519056618
   PubMed Web of Science ®Google Scholar
• NevenEDamsGPostnovAAdequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure ratsNephrol Dial Transplant2009114 [Epub ahead of print].10.1093/ndt/gfn73719903659
   PubMed Web of Science ®Google Scholar
• DammentSJPGreavesPDownesNThe toxicology of lanthanum carbonate (Fosrenol), a new non-aluminium, non-calcium phosphate binder [abstract]J Am Soc Nephrol200314204A
   Web of Science ®Google Scholar
• BehetsGJDamsGVercauterenSRDoes the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?J Am Soc Nephrol200415822192228
   Web of Science ®Google Scholar
• BehetsGJGrittersMDamsGDe BroeMED’HaesePCEffects of efficient phosphate binding on bone in chronic renal failure ratsRen Fail200527447548416060138
   PubMed Web of Science ®Google Scholar
• DammentSJShenVAssessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic ratsClin Nephrol200563212713715730055
   PubMed Web of Science ®Google Scholar
• BervoetsARosteLBehetsGJDevelopment and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure ratsBone200638680381016412714
   PubMed Web of Science ®Google Scholar
• SpasovskiGBSikoleAGelevSEvolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-upNephrol Dial Transplant20062182217222416595583
   PubMed Web of Science ®Google Scholar
• D’HaesePCSpasovskiGBSikoleAA multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patientsKidney Int Suppl200385S73S7812753271
   PubMed Web of Science ®Google Scholar
• BronnerFSlepchenkoBMPennickMDammentSJA model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonateClin Pharmacokinet200847854355218611063
   PubMed Web of Science ®Google Scholar
• MallucheHHSiamiGASwanepoelCImprovements in renal osteodystrophy in patients treated with lanthanum carbonate for two yearsClin Nephrol200870428429518826853
   PubMed Web of Science ®Google Scholar
• RodriguezMFelsenfeldAJLlachFAluminium administration in the rat separately affects the osteoblast and bone mineralizationJ Bone Miner Res19905159672309580
   PubMed Web of Science ®Google Scholar
• WangXYuanLHuangJZhangTLWangKLanthanum enhances in vitro osteoblast differentiation via pertussis toxin-sensitive gi protein and ERK signaling pathwayJ Cell Biochem200810551307131518810761
   PubMed Web of Science ®Google Scholar
• BehetsGJVerberckmoesSCosteLLocalization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonateKidney Int20056751830183615840030
   PubMed Web of Science ®Google Scholar
• PersyVPBehetsGJBervoetsARDe BroeMED’HaesePCLanthanum: a safe phosphate binderSemin Dial200619319519916689967
   PubMed Web of Science ®Google Scholar
• SlatopolskyELiapisHFinchJProgressive accumulation of lanthanum in the liver of normal and uremic ratsKidney Int20056862809281316316357
   PubMed Web of Science ®Google Scholar
• LacourBLucasAAuchereDRuellanNSerre PateyNMDruekeTBChronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administrationKidney Int20056731062106915698446
   PubMed Web of Science ®Google Scholar
• BervoetsARBehetsGJSchryversDHepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failureKidney Int20087538939819052535
   PubMed Web of Science ®Google Scholar
• YangZSchryversDRoelsFD’HaesePCDe BroeMEDemonstration of lanthanum in liver cells by energy-dispersive X-ray spectroscopy, electron energy loss spectroscopy and high-resolution transmission electron microscopyJ Microsc2006223Pt 213313916911073
   PubMed Web of Science ®Google Scholar
• AltmannPBarnettMEFinnWFCognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapyKidney Int200771325225917035945
   PubMed Web of Science ®Google Scholar